S&P 500
(0.19%) 5 258.27 points
Dow J
(0.16%) 39 825 points
Nasdaq
(-0.05%) 16 391 points
Oil
(2.00%) $82.98
Gas
(1.69%) $1.747
Gold
(1.23%) $2 239.90
Silver
(0.99%) $25.00
Platinum
(1.35%) $921.95
USD/EUR
(0.39%) $0.927
USD/NOK
(0.80%) $10.85
USD/GBP
(0.13%) $0.792
USD/RUB
(0.14%) $92.57

Realtime updates for Oncimmune Holdings PLC [ONC.L]

Exchange: LSE Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated28 Mar 2024 @ 08:34

-1.22% £ 20.74

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 08:34):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally...

Stats
Today's Volume 12 949.00
Average Volume 71 764.00
Market Cap 15.38M
EPS £0 ( 2023-09-28 )
Last Dividend £0 ( N/A )
Next Dividend £0 ( N/A )
P/E -1.480
ATR14 £0 (0.00%)

Oncimmune Holdings PLC Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncimmune Holdings PLC Financials

Annual 2022
Revenue: £1.15M
Gross Profit: £792 000 (68.75 %)
EPS: £0.0565
Q1 2023
Revenue: £28 000.00
Gross Profit: £28 000.00 (100.00 %)
EPS: £0.110
Q3 2022
Revenue: £1.12M
Gross Profit: £344 000 (30.60 %)
EPS: £-0.0580
Q1 2021
Revenue: £127 250
Gross Profit: £-7 000.00 (-5.50 %)
EPS: £-0.0334

Financial Reports:

No articles found.

Oncimmune Holdings PLC

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators